Replicate Design [Two-Stage / GS Designs]

posted by ElMaestro  – Denmark, 2014-06-23 15:32 (4372 d 07:24 ago) – Posting: # 13125
Views: 6,449

Hello Naveen,

❝ Please suggest, can we design full replicate bioequivalence study (molecule is highly variable) in stages for EMEA submission.


Yes, that should be a possibility but:
  1. There are no publications about two-stage BE trials combined with replicated designs. You might be asked to prove by your own simulations that type I errors are controlled at max 5% or so.
  2. Don't do it without a meeting with FDA.

❝ My concern is Power will play pivotal role in stage design, which not be in replicate (full) designs.


Not understood - can you explain what you mean?

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,571 registered users;
113 visitors (0 registered, 113 guests [including 17 identified bots]).
Forum time: 22:56 CEST (Europe/Vienna)

Outside his own ever-narrowing field of specialization,
a scientist is a layman.
What members of an academy of science have in common
is a certain form of semiparasitic living.    Erwin Chargaff

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5